Drugs / LDP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04718584 | Sep 2020 → Feb 2024 | penile carcinoma, renal carcinoma, urinary bladder cancer | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LDP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04718584 ↗ |
| Modality | Monoclonal antibody | “human anti-PD-L1 monoclonal antibody injection (LDP)” NCT04718584 ↗ |
| Route | Intravenous | “intravenous infusion of 10mg/kg human anti-PD-L1 monoclonal antibody injection (LDP) was given” NCT04718584 ↗ |